Arkolith/Insider Trading/AMLX/Form 4

Klee Justin B.

Co-Chief Executive Officer, DirectorAmylyx Pharmaceuticals, Inc. (AMLX) · full profile →Form 4 · filed Jan 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.9M
Net Open-Market Flow
-$1.9M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 16, 2026Option exercise(M)3K$7.57$22K3.4M
Jan 16, 2026Sell(S)2K$13.89$28K3.4M
Jan 15, 2026Option exercise(M)197K$7.57$1.5M3.5M
Jan 15, 2026Sell(S)136K$13.58$1.8M3.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 16, 2026Option exercise(M)3K—$00
Jan 15, 2026Option exercise(M)197K—$03K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-017056) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML